{"id":572844,"date":"2021-11-03T18:16:01","date_gmt":"2021-11-03T18:16:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=572844"},"modified":"2021-11-03T18:16:01","modified_gmt":"2021-11-03T18:16:01","slug":"pancreatic-cancer-pipeline-and-emerging-drugs-2021","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/pancreatic-cancer-pipeline-and-emerging-drugs-2021_572844.html","title":{"rendered":"Pancreatic cancer Pipeline and Emerging Drugs 2021"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1635927572.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Pancreatic cancer Pipeline and Emerging Drugs 2021\" src=\"https:\/\/www.abnewswire.com\/uploads\/1635927572.jpeg\" alt=\"Pancreatic cancer Pipeline and Emerging Drugs 2021\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\"><strong>Pancreatic Cancer Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Pancreatic cancer begins when abnormal cells in the pancreas grow and divide out of control and form a tumor. Pancreatic tumors are either exocrine or neuroendocrine (endocrine) tumors. This is based on the type of cell they start in. Knowing the type of tumor is important because each type acts differently and responds to different treatments. About 93% of pancreatic cancers are exocrine tumors. The most common type of pancreatic cancer is adenocarcinoma. About 7% of pancreatic tumors are neuroendocrine tumors (pancreatic NETs or PNETs), also called islet cell tumors. They often grow slower than exocrine tumors. A pancreatic tumor can only be seen on an imaging study such as computed tomography (CT) scan, magnetic resonance imaging (MRI) or endoscopic ultrasound (EUS). Pancreatic cancer treatment depends on the stage of the disease and the patient&rsquo;s general health.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Pancreatic Cancer Pipeline Insights<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s, &ldquo;<strong><span style=\"text-decoration: underline;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/pancreatic-cancer-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Pancreatic Cancer Pipeline<\/a><\/span><\/strong> Insight, 2021,&rdquo; report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Pancreatic Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download a sample- <span style=\"text-decoration: underline;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pancreatic-cancer-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Pancreatic Cancer Pipeline Insights<\/a><\/span><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Pancreatic Cancer Symptoms<\/strong><\/p>\n<p style=\"text-align: justify;\">Patients with adenocarcinoma of pancreas typically present with: Painless jaundice (70%) usually due to obstruction of the common bile duct from the pancreatic head tumor, Abdominal pain, Weakness, pruritus from bile salts in the skin, anorexia, palpable, non-tender, distended gallbladder, acholic stools, and dark urine, recent-onset of diabetes, Blood clots in the body, Itchy skin and nausea and vomiting.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Pancreatic Cancer Diagnosis<\/strong><\/p>\n<p style=\"text-align: justify;\">Multidetector computed tomography, MDCT, is the best imaging modality to diagnose and evaluate the extent of disease including perivascular extension and distant metastasis. MDCT is 77% accurate in predicting resectability and 93% accurate in predicting unresectability. PET CT scan can be useful in detecting distant metastatic disease. Abdominal MRI \/MRCP with IV contrast is as good in the preoperative evaluation of pancreatic cancer and the assessment of vascular invasion. ERCP with endoscopic ultrasound can be performed, and fine needle aspiration biopsies can be done of suspicious lesions for the pathologic specimen. Endoscopic retrograde cholangiopancreatography (ERCP) is a test in which a contrast dye is injected into the biliary ducts and pancreatic duct with an endoscope. The level of biliary or pancreatic obstruction can be delineated.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/pancreatic-cancer-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\"><strong>Pancreatic Cancer Treatment<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">The current treatment options for pancreatic cancer are surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. Neoadjuvant first approach in resectable pancreatic adenocarcinoma is to receive chemotherapy. There is a role for radiation therapy in combination with chemotherapy to treat locally advanced pancreatic cancer. The two main regimens used are FOLFIRINOX and gemcitabine plus protein-bound paclitaxel. Opioids, antiepileptics, and corticosteroids all are effective for pain relief in pancreatic cancer.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Pancreatic Cancer Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Rafael Pharmaceuticals<\/li>\n<li>AB Science<\/li>\n<li>Syncore Biotechnology<\/li>\n<li>Acerta Pharma<\/li>\n<li>Tyme Technologies<\/li>\n<li>And many others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><span style=\"text-decoration: underline;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/pancreatic-cancer-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\"><strong>Pancreatic Cancer Emerging Drugs<\/strong><\/a><\/span><\/p>\n<ul style=\"text-align: justify;\">\n<li>CPI-613 (devimistat): Rafael Pharmaceuticals<\/li>\n<li>Masitinib: AB Science<\/li>\n<li>EndoTAG-1: Syncore Biotechnology<\/li>\n<li>Acalabrutinib: Acerta Pharma<\/li>\n<li>SM-88 (racemetyrosine): Tyme Technologies<\/li>\n<li>Pamrevlumab: FibroGen<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>For More Information-&nbsp;<\/strong><span style=\"text-decoration: underline;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pancreatic-cancer-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\"><strong>Pancreatic Cancer Pipeline Report<\/strong><\/a><\/span><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of content<\/strong><\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Introduction<\/li>\n<li>Executive Summary<\/li>\n<li>Pancreatic Cancer: Overview<\/li>\n<li>Pipeline Therapeutics<\/li>\n<li>Therapeutic Assessment<\/li>\n<li>Pancreatic Cancer &ndash; DelveInsight&rsquo;s Analytical Perspective<\/li>\n<li>In-depth Commercial Assessment<\/li>\n<li>Pancreatic Cancer Collaboration Deals<\/li>\n<li>Late Stage Products (Phase III)<\/li>\n<li>Pamrevlumab: FibroGen<\/li>\n<li>Mid Stage Products (Phase II)<\/li>\n<li>Acalabrutinib: Acerta Pharma<\/li>\n<li>Early Stage Products (Phase I)<\/li>\n<li>RP72: Rise Biopharmaceuticals<\/li>\n<li>Inactive Products<\/li>\n<li>Pancreatic Cancer Key Companies<\/li>\n<li>Pancreatic Cancer Key Products<\/li>\n<li>Pancreatic Cancer- Unmet Needs<\/li>\n<li>Pancreatic Cancer- Market Drivers and Barriers<\/li>\n<li>Pancreatic Cancer- Future Perspectives and Conclusion<\/li>\n<li>Pancreatic Cancer Analyst Views<\/li>\n<li>Pancreatic Cancer Key Companies<\/li>\n<li>Appendix<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&amp;D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers &amp; Acquisitions.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Contact Us<\/strong><\/p>\n<p style=\"text-align: justify;\">Yash<\/p>\n<p style=\"text-align: justify;\">info@delveinsight.com<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56402.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=pancreatic-cancer-pipeline-and-emerging-drugs-2021\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=pancreatic-cancer-pipeline-and-emerging-drugs-2021\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pancreatic Cancer Overview Pancreatic cancer begins when abnormal cells in the pancreas grow and divide out of control and form a tumor. Pancreatic tumors are either exocrine or neuroendocrine (endocrine) tumors. This is based on the type of cell they &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/pancreatic-cancer-pipeline-and-emerging-drugs-2021_572844.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406],"tags":[],"class_list":["post-572844","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/572844","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=572844"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/572844\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=572844"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=572844"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=572844"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}